⌕
Stoke Therapeutics · STOK · Nasdaq
Tenet 50 · Mixed
Compare
$26.41−0.83%At closeTenet 50 · Mixed
$26.41−0.22 (−0.83%)
At close: Nov 17, 2026, 4:00 PM ET· Nasdaq · USD

Stoke Therapeutics (STOK) Institutional Ownership

13F filers reported holding 25.9% of Stoke Therapeutics (STOK) shares as of Sep 30, 2026, across 91 filers.

Sources Ownership filingsQuarter ended How we compute thisNot investment advice
Held by 13F filers
25.9%
Sep 30, 2026
13F filers
91
quarter ended Sep 30, 2026
13F value
$441.0M
16.9M shares
Quarter's fund flow
Mild distribution
6 new · 12 closed

Is the smart money (institutions and insiders) accumulating or distributing? One lagging input, not a buy signal.

13F fund flowQuarter ended Sep 30, 2026: more funds trimmed or exited than added or entered, mild distribution (6 new · 32 increased · 36 reduced · 12 closed · 5 unchanged or with no prior quarter on file). Flows at this scale move slowly; treat as context. These positions are 49 days old; the 45-day figure often quoted is the SEC filing deadline after quarter-end, not the age of the data. The counts above compare each filer’s position with its own previous 13F. The change in the number of filers and in the ownership share is not shown: the filings we read hold only each filer’s latest 13F, so there is no earlier quarter of the same filers to compare against. That is a limit of the source, not a statement about this company.
Basis: shares reported by 91 13F filers for Sep 30, 2026, over shares outstanding implied from the current quote, measured 49 days apart. It measures the ownership we have filings for, not total institutional ownership, and it moves with the share count between filings.
routine sells are usually compensation mechanics; open-market buys are the rarer signal. Rows labelled with another security are the derivative leg of a vest or exercise, not share sales
DateNameRoleTypeSharesPriceSEC filing
Oct 2, 2026Allan JonathanGENERAL COUNSEL & CORP SECDisposed · Open-market sale627$26.33↗
Oct 1, 2026Ticho BarryCHIEF MEDICAL OFFICERDisposed · Open-market sale1,051$26.16↗
Sep 1, 2026Ticho BarryCHIEF MEDICAL OFFICERDisposed · Open-market sale3,945$30.51↗
Sep 1, 2026Ticho BarryCHIEF MEDICAL OFFICERDisposed · Open-market sale1,600$31.06↗
Aug 18, 2026Allan JonathanGENERAL COUNSEL & CORP SECDisposed · Open-market sale2,716$32.01↗
Aug 18, 2026Allan JonathanGENERAL COUNSEL & CORP SECDisposed · Open-market sale145$32.47↗
Aug 18, 2026Ticho BarryCHIEF MEDICAL OFFICERDisposed · Open-market sale4,525$32.01↗
Aug 18, 2026Ticho BarryCHIEF MEDICAL OFFICERDisposed · Open-market sale242$32.47↗
Aug 18, 2026Kaye Edward M. MDdirectorDisposed · Open-market sale11,930$32.01↗
Aug 18, 2026Kaye Edward M. MDdirectorDisposed · Open-market sale637$32.47↗
Aug 14, 2026Allan JonathanGENERAL COUNSEL & CORP SECAcquired · Option exercise6,000—↗
Aug 14, 2026Allan JonathanGENERAL COUNSEL & CORP SECDisposed · Option exercise6,000Performance Stock Units—↗
Aug 14, 2026Ticho BarryCHIEF MEDICAL OFFICERAcquired · Option exercise10,000—↗
Aug 14, 2026Ticho BarryCHIEF MEDICAL OFFICERDisposed · Option exercise10,000Performance Stock Units—↗
Aug 14, 2026Kaye Edward M. MDdirectorAcquired · Option exercise26,250—↗
Aug 14, 2026Kaye Edward M. MDdirectorDisposed · Option exercise26,250Performance Stock Units—↗
Aug 3, 2026Ticho BarryCHIEF MEDICAL OFFICERDisposed · Open-market sale5,907$28.95↗
Aug 3, 2026Ticho BarryCHIEF MEDICAL OFFICERDisposed · Open-market sale1,269$29.45↗
Jul 16, 2026Harrison Seth LoringdirectorDisposed · Gift29,555Stock Option (Right to Buy)—↗
Jul 16, 2026Harrison Seth LoringdirectorAcquired · Gift29,555Stock Option (Right to Buy)—↗

* Holdings as reported for Sep 30, 2026, 49 days old; funds file up to 45 days after each quarter-end, so the newest complete quarter runs 45 to 135 days behind.

** A price of “—” marks an option exercise, RSU vest or a filing without a usable per-share price, not a $0 trade.

How much of Stoke Therapeutics do institutions hold?

13F filers reported holding 25.9% of Stoke Therapeutics' shares as of Sep 30, 2026, across 91 filers.

How many 13F filers hold Stoke Therapeutics?

Stoke Therapeutics was held by 91 13F filers as of Sep 30, 2026.

Not investment advice.

Install Tenet on your phone

Tenet home pageMethodology© 2026 Tenet Investing Inc.

Data from Intrinio and Financial Modeling Prep.